NCT01979211View on ClinicalTrials.gov

Post-operative Radiation With Cetuximab for Locally Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck

PHASE2CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

October 31, 2013

Primary Completion Date

January 19, 2022

Study Completion Date

January 19, 2022

Conditions
Head and Neck Cancer
Interventions
DRUG

Cetuximab

400 mg/m2 IV over 120 minutes week 1; 250 mg/m2 IV over 60 minutes weekly weeks 2-7

RADIATION

Radiation Therapy

Radiation Therapy 60-66 Gy in 2 Gy fractions starting week 2 of Cetuximab

Trial Locations (1)

45219

University of Cincinnati, Cincinnati

All Listed Sponsors
lead

University of Cincinnati

OTHER

NCT01979211 - Post-operative Radiation With Cetuximab for Locally Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck | Biotech Hunter | Biotech Hunter